Literature DB >> 3780048

Pepsinogen--an immunoglobulin binding artefact in 'collagen' preparations.

A P Kirk, B P O'Hara, R A Mageed, M S McMahon, D McCarthy, S Menashi, J R Archer, H L Currey.   

Abstract

It has previously been shown that extracts of human articular cartilage, many many of which contain type II collagen, react with heat-aggregated immunoglobulin and artificially prepared immune complexes. Sera from patients with rheumatoid arthritis and psoriatic arthritis, but not from patients with inflammatory bowel disease, react with these extracts. There are two distinct patterns of binding, either as low molecular weight immune complexes or as free antibody directed against collagen. Aggregate-binding activity identified in extracts of human articular cartilage following pepsin digestion was found to be distinct from collagen in its salt solubility. Further purification of this aggregate-binding factor by SDS gel electrophoresis has shown it to be an artefact resulting from the binding of small immune complexes to pepsinogen present in the pepsin preparation used to digest the cartilage.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780048      PMCID: PMC1542510     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Antigenicity of collagen and its application in the serological investigation of rheumatoid arthritis sera.

Authors:  C STEFFEN; R TIMPL
Journal:  Int Arch Allergy Appl Immunol       Date:  1963

2.  Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q.

Authors:  F C Hay; L J Nineham; I M Roitt
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

3.  Immunglobulin classes, subclasses and complexes of IgG rheumatoid factor in rheumatoid plasma cells.

Authors:  E Munthe; J B Natvig
Journal:  Clin Exp Immunol       Date:  1972-09       Impact factor: 4.330

4.  Anti-collagen antibodies in sera from rheumatoid arthritis patients.

Authors:  H K Beard; R Ryvar; J Skingle; C L Greenbury
Journal:  J Clin Pathol       Date:  1980-11       Impact factor: 3.411

5.  Differences in domain structures between plasma and cellular fibronectins.

Authors:  M Hayashi; K M Yamada
Journal:  J Biol Chem       Date:  1981-11-10       Impact factor: 5.157

6.  The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.

Authors:  B E Bourke; I K Moss; P Mumford; A Horsfall; R N Maini
Journal:  Clin Exp Immunol       Date:  1982-06       Impact factor: 4.330

7.  Activation of latent collagenase by serum proteinases that interact with immobilized immunoglobulin G.

Authors:  P C Armour; S Levi; E E Golds; A R Poole; J S Mort; P J Roughley
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

8.  Binding of immunoglobulins and immune complexes to cartilage derived extracts.

Authors:  W R Alomari; J R Archer; R Brocklehurst; H L Currey
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

9.  Incidence and specificity of antibodies to types I, II, III, IV, and V collagen in rheumatoid arthritis and other rheumatic diseases as measured by 125I-radioimmunoassay.

Authors:  J M Stuart; E H Huffstutter; A S Townes; A H Kang
Journal:  Arthritis Rheum       Date:  1983-07

10.  Anomalous reactions in the haemagglutination assay for anti-collagen antibodies: studies on patients with rheumatoid arthritis or chronic low back pain.

Authors:  H K Beard; D J Lea; R Ryvar
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

View more
  1 in total

1.  Antibodies against 4 Atypical Post-Translational Protein Modifications in Patients with Rheumatoid Arthritis.

Authors:  Lorena Rodríguez-Martínez; Cristina Regueiro; Sámer Amhaz-Escanlar; Carmen Pena; Paloma Herbello-Hermelo; Antonio Moreda-Piñeiro; Javier Rodriguez-Garcia; Antonio Mera-Varela; Eva Pérez-Pampín; Antonio González
Journal:  Diagnostics (Basel)       Date:  2022-01-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.